These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Outcomes and Adverse Effects of Voretigene Neparvovec Treatment for Biallelic Kiraly P; Cottriall CL; Taylor LJ; Jolly JK; Cehajic-Kapetanovic J; Yusuf IH; Martinez-Fernandez de la Camara C; Shanks M; Downes SM; MacLaren RE; Fischer MD Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892166 [TBL] [Abstract][Full Text] [Related]
26. Inflammation after Voretigene Neparvovec Administration in Patients with RPE65-Related Retinal Dystrophy. Kessel L; Christensen UC; Klemp K Ophthalmology; 2022 Nov; 129(11):1287-1293. PubMed ID: 35760216 [TBL] [Abstract][Full Text] [Related]
27. Short-Term Outcomes of the First in Vivo Gene Therapy for RPE65-Mediated Retinitis Pigmentosa. Kwak JJ; Kim HR; Byeon SH Yonsei Med J; 2022 Jul; 63(7):701-705. PubMed ID: 35748082 [TBL] [Abstract][Full Text] [Related]
28. Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years. Maguire AM; Russell S; Chung DC; Yu ZF; Tillman A; Drack AV; Simonelli F; Leroy BP; Reape KZ; High KA; Bennett J Ophthalmology; 2021 Oct; 128(10):1460-1468. PubMed ID: 33798654 [TBL] [Abstract][Full Text] [Related]
29. Classification and Growth Rate of Chorioretinal Atrophy after Voretigene Neparvovec-Rzyl for RPE65-Mediated Retinal Degeneration. Bommakanti N; Young BK; Sisk RA; Berrocal AM; Duncan JL; Bakall B; Mathias MT; Ahmed I; Chorfi S; Comander J; Nagiel A; Besirli CG Ophthalmol Retina; 2024 Jan; 8(1):42-48. PubMed ID: 37660736 [TBL] [Abstract][Full Text] [Related]
30. Current Management of Patients with RPE65 Mutation-Associated Inherited Retinal Degenerations in Europe: Results of a Multinational Survey by the European Vision Institute Clinical Research Network. Lorenz B; Tavares J; van den Born LI; Marques JP; Scholl HPN; Ophthalmic Res; 2021; 64(5):740-753. PubMed ID: 33684911 [TBL] [Abstract][Full Text] [Related]
31. Objective Outcomes to Evaluate Voretigene Neparvovec Treatment Effects in Clinical Practice. Melillo P; Testa F; Di Iorio V; Karali M; Citro A; Della Corte M; Rossi S; Banfi S; Simonelli F Ophthalmol Retina; 2024 Jul; 8(7):688-698. PubMed ID: 38295874 [TBL] [Abstract][Full Text] [Related]
32. Oral 9-cis retinoid for childhood blindness due to Leber congenital amaurosis caused by RPE65 or LRAT mutations: an open-label phase 1b trial. Koenekoop RK; Sui R; Sallum J; van den Born LI; Ajlan R; Khan A; den Hollander AI; Cremers FP; Mendola JD; Bittner AK; Dagnelie G; Schuchard RA; Saperstein DA Lancet; 2014 Oct; 384(9953):1513-20. PubMed ID: 25030840 [TBL] [Abstract][Full Text] [Related]
33. The phenotype of Severe Early Childhood Onset Retinal Dystrophy (SECORD) from mutation of RPE65 and differentiation from Leber congenital amaurosis. Weleber RG; Michaelides M; Trzupek KM; Stover NB; Stone EM Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):292-302. PubMed ID: 20811047 [TBL] [Abstract][Full Text] [Related]